<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
x

Clarity with
Crown

Recognize your next clinical candidate when you see it.

Our Translational Platforms enable our clients to identify the right patients for the right treatment. Having models which more accurately mimic human disease and population dynamics are key to successfully translating promising compounds into successful clinical candidates, whether treating Oncology or Diabetes related diseases.

Magnify your
insights

Understand the mechanisms of disease.

Our scientific acumen and experience will give you a deeper understanding of not just the pharmacological profile of your compound, but more importantly, a clear understanding of which compounds to progress into the clinic. Take a look at our publications to get a deeper understanding of the depth of our scientific expertise.

Begin with the
end insight

Connecting science to patients.

We help our clients solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease by answering some of the most challenging questions about human biology.

CVMD

Models of Obesity

obesity-img.jpg

CrownBio’s preclinical Translational Technology Platforms provide spontaneous & diet-induced obesity (DIO) models, to support the transition of new agents into the clinic.

Learn More

Oncology

Oncology Databases

databases-img.jpg

Our unique databases provide a curated source of well-characterized models available to use for drug discovery including PDX models, cell lines, and syngeneic models.

Learn More

CVMD

Diabetes Models

oncoexpress-img.jpg

Models of both Type 1 and Type 2 diabetes, including conventional, as well as unique, highly translatable models for in vivo efficacy studies of antidiabetic agents.

Learn More

Latest from our Blog

April 1, 2021

Expanding the Horizon of Antibody-Drug Conjugates for Cancer Treatment

This post explores the fast-expanding topic of antibody-drug conjugates (ADCs), including those that have been approved to date and recent and future innovations that may come to bear on ADCs.

Read More

April 1, 2021

Expanding the Horizon of Antibody-Drug Conjugates for Cancer Treatment

This post explores the fast-expanding topic of antibody-drug conjugates (ADCs), including those...

Read More

March 1, 2021

Profiling of Tumor-Infiltrating Immune Cells in Syngeneic Tumor Models to Support Drug Development

Tumor-Infiltrating Immune Cells: Explore how the identification and quantification of...

Read More

December 18, 2020

Factors to Consider When Selecting a Next Generation Sequencing (NGS) Technology

Explore the main factors you need to consider before choosing and using next generation...

Read More

December 16, 2020

Germ-Free or Antibiotic-Treated Mice? Which Model for Studying the Role of the Gut Microbiota in Preclinical Studies

Explore the differences and similarities of germ-free (GF) and antibiotic-treated mice as models...

Read More

December 3, 2020

The Latest Developments on PARP Inhibitors for Prostate Cancer Treatment

Review the status of PARP inhibitors (PARPi) for prostate cancer treatment, with a focus on...

Read More

Upcoming Events


Week 1: April 10-15, 2021 | Week 2: May 17-21, 2021

CrownBio's Virtual AACR21 Event

Virtual


Week 1: April 10-15, 2021 | Week 2: May 17-21, 2021

AACR Annual Meeting 2021

Virtual


April 13, 2021

Organoid Discovery

Virtual


Monday April 12, 8.30 – 13.00 EST | Tuesday April 13, 13.00 – 17.00 EST

CrownBio Presents: PREDiCT Innovation: Leverage Novel Preclinical Oncology Approaches to Guide Clinical Success

Virtual


April 20th, 10AM/5PM ET

Unlocking Tomorrow´s Cure for Cancer: Patient-Derived Organoid and Immune Cell Co-Cultures for Immunotherapy Development

Virtual